真实世界研究再次证明了 GLP-1 疗法对心理健康和自杀风险的安全性

Iskandar Idris DM
{"title":"真实世界研究再次证明了 GLP-1 疗法对心理健康和自杀风险的安全性","authors":"Iskandar Idris DM","doi":"10.1002/doi2.70005","DOIUrl":null,"url":null,"abstract":"<p>In July of 2023, the European Medicines Agency announced that it was conducting a formal review into reports that the use of these drugs could increase the risk for suicide and suicidal thoughts. This was based on The Icelandic Medicines Agency receiving reports of up to 150 people who took the drugs and experienced suicidal thoughts or self-injury.</p><p>This was surprising since there was no signal of this potential adverse effect in the randomized trial data. However, since randomized trials have strict inclusion criteria to exclude people with psychological issues at baseline, trial safety data may not observe concerns about psychiatric safety risks.</p><p>As such, the other approach is to look at real world data. To this end, a study published in JAMA medicine have reported this.<span><sup>1</sup></span></p><p>In the study, investigators identified everyone in Sweden and Denmark who started taking semaglutide or liraglutide (<i>N</i> = 124 517) for diabetes from 2013 to 2021. Use of SGLT2 inhibitor (<i>N</i> = 174 036) at the same time but not GLP-1 therapy was used as a control group.</p><p>In any case, 124 517 adults were prescribed Ozempic or an Ozempic-like drug, and 174 036 started taking an SGLT2 inhibitor. Interestingly, those who were prescribed Ozempic were more likely to be using or to have previously used antidepressants and to have had an outpatient visit for a psychiatric diagnosis. Analysis was undertaken via a propensity score analysis to adjust for confounders. The study showed that 77 new Ozempic users died from suicide (6 out of 10 000 people) as did 71 new SGLT2 inhibitor users (4 out of 10 000 people). While there was a slight increase risk with GLP-1, the margin of error is very large. Crucially, when death from suicide and nonfatal self-harm were combined, GLP-1 receptor agonists appear to be protective (HR, 0.83; 95% CI, 0.07–0.97), while no difference was noted between GLP-1 and SGLT2 inhibitor on new psychiatric disorder.</p><p>In my opinion therefore, the outcome is equivocal and that there is no significant association between Ozempic and suicide. These findings are reassuring but further monitoring and surveillance is needed to monitor its safety.</p>","PeriodicalId":100370,"journal":{"name":"Diabetes, Obesity and Metabolism Now","volume":"2 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/doi2.70005","citationCount":"0","resultStr":"{\"title\":\"Real world study provided reassurance of the safety of GLP-1 therapy on mental health and suicide risk\",\"authors\":\"Iskandar Idris DM\",\"doi\":\"10.1002/doi2.70005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In July of 2023, the European Medicines Agency announced that it was conducting a formal review into reports that the use of these drugs could increase the risk for suicide and suicidal thoughts. This was based on The Icelandic Medicines Agency receiving reports of up to 150 people who took the drugs and experienced suicidal thoughts or self-injury.</p><p>This was surprising since there was no signal of this potential adverse effect in the randomized trial data. However, since randomized trials have strict inclusion criteria to exclude people with psychological issues at baseline, trial safety data may not observe concerns about psychiatric safety risks.</p><p>As such, the other approach is to look at real world data. To this end, a study published in JAMA medicine have reported this.<span><sup>1</sup></span></p><p>In the study, investigators identified everyone in Sweden and Denmark who started taking semaglutide or liraglutide (<i>N</i> = 124 517) for diabetes from 2013 to 2021. Use of SGLT2 inhibitor (<i>N</i> = 174 036) at the same time but not GLP-1 therapy was used as a control group.</p><p>In any case, 124 517 adults were prescribed Ozempic or an Ozempic-like drug, and 174 036 started taking an SGLT2 inhibitor. Interestingly, those who were prescribed Ozempic were more likely to be using or to have previously used antidepressants and to have had an outpatient visit for a psychiatric diagnosis. Analysis was undertaken via a propensity score analysis to adjust for confounders. The study showed that 77 new Ozempic users died from suicide (6 out of 10 000 people) as did 71 new SGLT2 inhibitor users (4 out of 10 000 people). While there was a slight increase risk with GLP-1, the margin of error is very large. Crucially, when death from suicide and nonfatal self-harm were combined, GLP-1 receptor agonists appear to be protective (HR, 0.83; 95% CI, 0.07–0.97), while no difference was noted between GLP-1 and SGLT2 inhibitor on new psychiatric disorder.</p><p>In my opinion therefore, the outcome is equivocal and that there is no significant association between Ozempic and suicide. These findings are reassuring but further monitoring and surveillance is needed to monitor its safety.</p>\",\"PeriodicalId\":100370,\"journal\":{\"name\":\"Diabetes, Obesity and Metabolism Now\",\"volume\":\"2 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/doi2.70005\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity and Metabolism Now\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/doi2.70005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity and Metabolism Now","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/doi2.70005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

2023 年 7 月,欧洲药品管理局宣布,它正在对有关使用这些药物可能会增加自杀和自杀念头风险的报告进行正式审查。这是因为冰岛药品管理局收到了多达 150 人的报告,称他们在服用这些药物后出现了自杀念头或自残行为。然而,由于随机试验有严格的纳入标准,以排除基线时有心理问题的人,因此试验安全数据可能无法观察到有关精神疾病安全风险的担忧。为此,发表在《美国医学会杂志》(JAMA medicine)上的一项研究对此进行了报道。1 在这项研究中,研究人员确定了瑞典和丹麦从 2013 年至 2021 年开始服用塞马鲁肽或利拉鲁肽(N = 124 517)治疗糖尿病的所有人。同时使用SGLT2抑制剂(N = 174 036)但不使用GLP-1疗法的患者作为对照组。无论如何,有124 517名成人被处方Ozempic或类似Ozempic的药物,174 036人开始服用SGLT2抑制剂。有趣的是,那些被处方 Ozempic 的人更有可能正在使用或曾经使用过抗抑郁药,也更有可能曾因精神疾病门诊就医。研究采用倾向得分分析法进行分析,以调整混杂因素。研究结果显示,77 名新的 Ozempic 使用者死于自杀(每 10,000 人中有 6 人),71 名新的 SGLT2 抑制剂使用者也死于自杀(每 10,000 人中有 4 人)。虽然使用 GLP-1 的风险略有增加,但误差范围非常大。最重要的是,如果将自杀死亡和非致命性自残合并计算,GLP-1受体激动剂似乎具有保护作用(HR,0.83;95% CI,0.07-0.97),而GLP-1和SGLT2抑制剂在新发精神障碍方面没有差异。这些结果令人欣慰,但还需要进一步监测和监控其安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Real world study provided reassurance of the safety of GLP-1 therapy on mental health and suicide risk

In July of 2023, the European Medicines Agency announced that it was conducting a formal review into reports that the use of these drugs could increase the risk for suicide and suicidal thoughts. This was based on The Icelandic Medicines Agency receiving reports of up to 150 people who took the drugs and experienced suicidal thoughts or self-injury.

This was surprising since there was no signal of this potential adverse effect in the randomized trial data. However, since randomized trials have strict inclusion criteria to exclude people with psychological issues at baseline, trial safety data may not observe concerns about psychiatric safety risks.

As such, the other approach is to look at real world data. To this end, a study published in JAMA medicine have reported this.1

In the study, investigators identified everyone in Sweden and Denmark who started taking semaglutide or liraglutide (N = 124 517) for diabetes from 2013 to 2021. Use of SGLT2 inhibitor (N = 174 036) at the same time but not GLP-1 therapy was used as a control group.

In any case, 124 517 adults were prescribed Ozempic or an Ozempic-like drug, and 174 036 started taking an SGLT2 inhibitor. Interestingly, those who were prescribed Ozempic were more likely to be using or to have previously used antidepressants and to have had an outpatient visit for a psychiatric diagnosis. Analysis was undertaken via a propensity score analysis to adjust for confounders. The study showed that 77 new Ozempic users died from suicide (6 out of 10 000 people) as did 71 new SGLT2 inhibitor users (4 out of 10 000 people). While there was a slight increase risk with GLP-1, the margin of error is very large. Crucially, when death from suicide and nonfatal self-harm were combined, GLP-1 receptor agonists appear to be protective (HR, 0.83; 95% CI, 0.07–0.97), while no difference was noted between GLP-1 and SGLT2 inhibitor on new psychiatric disorder.

In my opinion therefore, the outcome is equivocal and that there is no significant association between Ozempic and suicide. These findings are reassuring but further monitoring and surveillance is needed to monitor its safety.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity Multi-society consensus guidance on handling of GLP-1 therapy prior to general anaesthesia Issue Information Issue Information Precision medicine approach to detect obese people who are at high risk of developing diabetes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1